Navigation Links
Skinvisible to Present at Merriman Curhan Ford & Co.'s Investor Summit 2007
Date:9/10/2007

Hundreds of Institutional Investors to Attend Conference

LAS VEGAS, Sept. 10 /PRNewswire-FirstCall/ -- Skinvisible, Inc. (OTC Bulletin Board: SKVI / Website: http://www.skinvisible.com), the developers of Invisicare(R), a proprietary polymer delivery system for topically applied dermatology products, today announced that Mr. Terry Howlett, President & CEO, will present at the 4th annual Merriman Curhan Ford & Co. Investor Summit on September 18, 2007 at 2:15 PM. This event will be held at the Mark Hopkins InterContinental Hotel in San Francisco.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030416/LAW068LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20040503/INVISICARELOGO)

More information about the conference can be found at: http://www.merrimanco.com

About Merriman Curhan Ford & Co.

Merriman Curhan Ford & Co., a subsidiary of MCF Corporation (Amex: MEM), is an investment bank and securities broker-dealer focused on fast-growing companies and growth-oriented institutional investors. It provides investment research, brokerage and trading services primarily to institutions, as well as advisory and investment banking services to corporate clients. Its mission is to become a leader in the researching, advising, financing and trading of fast-growing companies. Merriman Curhan Ford & Co. is registered with the Securities and Exchange Commission as a broker-dealer and is a member of the National Association of Securities Dealers, Inc. and SIPC.

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals, a wholly owned subsidiary of Skinvisible Inc., is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the patent. http://www.skinvisible.com

About Invisicare(R)

Invisicare is a patented polymer delivery system developed to hold active ingredients topically on the skin for extended periods of time. A key benefit is that Invisicare is non-occlusive on the skin, allowing normal skin respiration and perspiration. The Company has developed a portfolio of topical products using Invisicare for the dermatology and cosmeceutical industries. http://www.invisicare.com

Forward-Looking Statements

This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending June 30, 2007)

Corporate Contact:

Terry Howlett, President/CEO

Skinvisible Pharmaceuticals, Inc

Phone: 702-433-7154

Email: info@skinvisible.com


'/>"/>
SOURCE Skinvisible, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
2. Researchers Present Ways To Reduce The Risk Of Dementia
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
5. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
6. Drug Reactions First Present Themselves In The Mouth
7. Reminiscing Into The Past Makes You Dissatisfied With The Present
8. Living In The Past Indicates Dissatisfaction With Present
9. Movies Represent Coma In A Wrong Way
10. Onchocerciasis: Presentation And Treatment
11. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... May 06, 2016 , ... ... TX has announced the latest beneficiary of their ongoing community enrichment program. The ... childhood leukemia. Young Mason McGaughey faces many more months of treatments, leaving his ...
(Date:5/6/2016)... ... 06, 2016 , ... The joy associated with Mother’s Day is mixed with worry and fear ... units (NICUs) across the country. For the first time ever, the March of Dimes ... who spend their Mother’s Day beside a crib surrounded by lifesaving equipment or peering through ...
(Date:5/6/2016)... ... May 06, 2016 , ... A wide variety of national pet product manufacturers, companies and brands ... Media Showcase Wednesday, May 18 from noon to 8 p.m. at New York City’s Roger ... new and established home, garden, outdoor and safety pet products in today’s marketplace. ...
(Date:5/6/2016)... ... May 06, 2016 , ... Fat-Freezing, which is what ... body, is the most popular among body sculpting options, according to a new ... cosmetic surgeon Dr. Richard Buckley, medical director of MilfordMD Cosmetic Dermatology Surgery & ...
(Date:5/6/2016)... ... May 06, 2016 , ... From May 4 to 6, ... members the unique opportunity to learn more about Signia’s technology and the successful business ... “It is our priority to see practices succeed in this highly competitive industry,” said ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... , May 5, 2016 ... addition of the  "Europe Systemic Lupus Erythematosus ...  report to their offering.       ... The latest research Europe Systemic Lupus Erythematosus ... provides comprehensive insights into Systemic Lupus Erythematosus ...
(Date:5/4/2016)... COUNTY, Calif. , May 4, 2016  It,s time for an upgrade. There ... shown on a brilliant 3.5 inch LCD, the illustrious DVMAXX HD  offers unparalleled ... brands as well as a world class manufacturer of innovative technology.  Photo ... ... ...
(Date:5/4/2016)... , May 4, 2016 ... Jerusalem announced today that it had signed an ... Inc. , developer of novel protein degradation and immunomodulatory ... and commercialization of drug candidates representing first-in-class therapy for ... were not disclosed. The novel technology was ...
Breaking Medicine Technology: